Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-based self-adjuvanting vaccines.

Lorena E Brown1, David C Jackson

  • 1The Cooperative Research Centre for Vaccine Technology, The Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria, Australia 3010. l.brown@microbiology.unimelb.edu.au

Current Drug Delivery
|November 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding and controlling pandemic influenza.

Proceedings of the Japan Academy. Series B, Physical and biological sciences·2026
Same author

Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses.

Science translational medicine·2026
Same author

ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses and neutralizing antibody induction.

Journal of virology·2025
Same author

Bovine tracheal organoids for studying Mycoplasma bovis respiratory infections.

Veterinary microbiology·2024
Same author

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.

EBioMedicine·2023
Same author

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.

EBioMedicine·2023
Same journal

Mechanistic and Phytochemical Basis of Shexiang Xintongning Against Atherosclerosis: Insights from Network Pharmacology and Molecular Docking.

Current drug delivery·2026
Same journal

Design and Optimization of Beta-Caryophyllene Nanoemulgel for Enhanced Antihyperlipidemic Activity: A Response Surface Approach.

Current drug delivery·2026
Same journal

Optimization of Andrographolide Nanocrystal-loaded Liposomes by Box-Behnken Design and its <i>In vitro</i> and <i>In vivo</i> Evaluation.

Current drug delivery·2026
Same journal

Development and Assessment of Rutin/Betamethasone-Loaded PAN-PVP Nanofibers for Wound Healing Applications.

Current drug delivery·2026
Same journal

QbD-Driven Rational Design of Vancomycin-Loaded Nanocubosome <i>In situ</i> Ocular Gels: Augmenting Precorneal Retention and Improving Anti-MRSA Keratitis Treatment.

Current drug delivery·2026
Same journal

Curcumin-based Nanotherapeutics to Combat Neurodegenerative Disease: Drug Delivery Strategies and Therapeutic Potential.

Current drug delivery·2026
See all related articles

Synthetic lipopeptides are effective, adjuvant-free vaccine candidates. These immunogens are well-tolerated, stimulate robust immune responses via multiple routes, and target dendritic cells for enhanced efficacy.

Area of Science:

  • Immunology
  • Vaccinology
  • Synthetic Chemistry

Background:

  • Lipopeptides incorporating T-cell and B-cell or CD8+ T-cell epitopes are potent immunogens.
  • These vaccine candidates offer advantages over traditional technologies, being synthetic, pure, and adjuvant-free.

Purpose of the Study:

  • To review the design, efficacy, and challenges of lipopeptide-based immunogens.
  • To discuss the self-adjuvanting properties of lipopeptides mediated by dendritic cell targeting.

Main Methods:

  • Review of existing literature on lipopeptide vaccine candidates.
  • Analysis of immunogenicity and tolerability data in animal models and humans.
  • Discussion of the mechanism of action, including dendritic cell interaction.

Related Experiment Videos

Main Results:

  • Lipopeptides are immunogenic and well-tolerated in various species and can be administered via multiple routes, including mucosal surfaces.
  • The lipid component confers a "self-adjuvanting" property by targeting dendritic cells, enhancing immune response induction.
  • Immune responses can be precisely focused on pathogen or tumor epitopes for effective immunity or to modulate hormone activity.

Conclusions:

  • Lipopeptides represent a promising platform for developing novel, effective, and safe vaccines.
  • Understanding the interaction with dendritic cells is key to optimizing lipopeptide-based immunotherapies.
  • Future research should focus on addressing challenges and expanding the application of lipopeptide technology.